| Literature DB >> 35135062 |
Dominique A Cadilhac1,2, Joosup Kim1,2, Geoffrey Cloud3,4, Craig S Anderson5, Emma K Tod2, Sibilah J Breen2, Steven Faux6,7, Timothy Kleinig8, Helen Castley9, Richard I Lindley10, Sandy Middleton11, Bernard Yan12, Kelvin Hill13, Brett Jones14, Darshan Shah15,16, Katherine Jaques17, Benjamin Clissold1,18, Bruce Campbell2,12, Natasha A Lannin3,4.
Abstract
BACKGROUND ANDEntities:
Keywords: COVID-19; Quality of health care; Stroke
Year: 2022 PMID: 35135062 PMCID: PMC8829483 DOI: 10.5853/jos.2021.02530
Source DB: PubMed Journal: J Stroke ISSN: 2287-6391 Impact factor: 6.967
Patient characteristics by ward setting and pandemic period
| Characteristic | Pre-pandemic (Jan 1, 2019–Feb 24, 2020) | Pandemic (Feb 25, 2020–Jun 23, 2020) | Comparison of periods[ | |||||
|---|---|---|---|---|---|---|---|---|
| Treated in a stroke unit | Treated in a stroke unit | |||||||
| No (n=5,226) | Yes (n=16,666) |
| No (n=1,750) | Yes (n=3,870) |
|
| ||
| Age (yr) | 0.083 | 0.062 | 0.643 | |||||
| <65 | 1,342 (26) | 4,198 (26) | 404 (23) | 1,009 (26) | ||||
| 65–74 | 1,236 (24) | 3,935 (24) | 433 (25) | 955 (25) | ||||
| 75–84 | 1,438 (28) | 4,951 (30) | 523 (30) | 1,130 (29) | ||||
| ≥85 | 1,051 (21) | 3,283 (20) | 373 (22) | 741 (19) | ||||
| Male | 2,635 (52) | 9,322 (57) | <0.001 | 924 (53) | 2,162 (56) | 0.034 | 0.636 | |
| Diagnosis | <0.001 | <0.001 | 0.001 | |||||
| Intracerebral hemorrhage | 794 (16) | 1,786 (11) | 214 (15) | 443 (12) | ||||
| Ischemic stroke | 2,387 (48) | 12,781 (77) | 671 (47) | 2,885 (75) | ||||
| Transient ischemic attack | 1,633 (33) | 1,807 (11) | 490 (34) | 455 (12) | ||||
| Undetermined stroke | 194 (4) | 236 (1) | 60 (4) | 50 (1) | ||||
| In-hospital stroke | 353 (7) | 433 (3) | <0.001 | 77 (6) | 92 (2) | <0.001 | 0.367 | |
| Previous history of stroke | 1,029 (21) | 3,636 (22) | 0.150 | 214 (19) | 743 (21) | 0.105 | 0.012 | |
| Arrival by ambulance | 3,346 (73) | 12,478 (78) | <0.001 | 913 (77) | 2,913 (81) | 0.002 | <0.001 | |
| Transferred from another hospital | 547 (11) | 3,139 (19) | <0.001 | 118 (8) | 656 (17) | <0.001 | <0.001 | |
| Ability to walk on admission | 2,181 (48) | 6,432 (41) | <0.001 | 496 (47) | 1,384 (40) | <0.001 | 0.298 | |
| Median length of stay (day) (quartile 1-3) | 2 (1–5) | 4 (2–8) | <0.001 | 2 (1–5) | 4 (2–8) | <0.001 | <0.001 | |
Values are presented as number (%) unless otherwise specified.
Patients within periods were aggregated in this comparison.
Treatment by ward setting and pandemic period
| Variable | Pre-pandemic (Jan 1, 2019–Feb 24, 2020) | Pandemic (Feb 25, 2020–Jun 23, 2020) | Comparison of periods[ | ||||
|---|---|---|---|---|---|---|---|
| Treated in a stroke unit | Treated in a stroke unit | ||||||
| No | Yes |
| No | Yes |
|
| |
| Provided antithrombotic medication within 48 hours of arrival[ | 2,092/3,371 (62) | 8,289/11,697 (71) | <0.001 | 543/843 (64) | 1,840/2,484 (74) | <0.001 | 0.002 |
| Mobilised during the admission | 3,113/4,951 (63) | 11,679/14,692 (79) | <0.001 | 719/1,578 (46) | 2,412/3,402 (71) | <0.001 | <0.001 |
| Provided swallow screen or assessment | 2,478/4,631 (54) | 12,697/14,129 (90) | <0.001 | 583/1,385 (42) | 2,709/3,029 (89) | <0.001 | <0.001 |
| Discharged to inpatient rehabilitation | 506/5,012 (10) | 4,234/16,249 (26) | <0.001 | 155/1,330 (12) | 987/3,578 (28) | <0.001 | 0.141 |
| Prescribed antihypertensive medication at discharge | 2,656/4,059 (65) | 11,159/14,607 (76) | <0.001 | 613/1,245 (49) | 2,352/3,260 (72) | <0.001 | <0.001 |
| Prescribed antithrombotic medication at discharge[ | 3,157/3,773 (84) | 12,642/13,636 (93) | <0.001 | 724/1,175 (62) | 2,626/3,022 (87) | <0.001 | <0.001 |
| Prescribed lipid lowering medication at discharge[ | 2,587/3,769 (69) | 11,039/13,649 (81) | <0.001 | 616/1,177 (52) | 2,268/3,004 (76) | <0.001 | <0.001 |
| Discharged to the community with a care plan | 1,303/2,656 (49) | 5,576/7,499 (74) | <0.001 | 322/624 (52) | 1,284/1,606 (80) | <0.001 | <0.001 |
Values are presented as number/total number (%).
Patients within periods were aggregated in this comparison;
Excluding patients with intracerebral hemorrhage.
Figure 1.Proportion of patients (A) provided antithrombotic medication within 48 hours of arrival (excluding patients with intracerebral hemorrhage), (B) mobilized during the admission, (C) provided swallow screen or assessment, and (D) discharged to rehabilitation. The vertical line (week 61) indicates the week of the interruption used in this study (1/3/2020, the first coronavirus disease 2019 [COVID-19] related death in Australia). Significant difference in weekly trend between groups prior to interruption (β and 95% confidence intervals [CIs] presented): provided antithrombotic medication within 48 hours of arrival 0.09 (95% CI, 0.04 to 0.14); mobilized during the admission –0.15 (95% CI, –0.23 to –0.07). Significant difference during week of interruption between groups (week 61): provided antithrombotic medication within 48 hours of arrival –5.35 (95% CI, –9.08 to –1.61); provided swallow screen or assessment –5.81 (95% CI, –8.62 to –2.99); discharged to rehabilitation –2.2 (95% CI, –3.72 to –0.68). Significant difference in weekly trend between groups in post-interruption period: provided swallow screen or assessment 0.86 (95% CI, 0.48 to 1.24); discharged to rehabilitation 0.6 (95% CI, 0.37 to 0.83). β in a period signifies the difference in the average weekly percentage change over several weeks (trend) between groups. β during the week of the interruption signifies the difference in a percentage change during that week between groups. Positive values indicate a greater relative percentage increase in the provision of evidence-based care in stroke units compared with other ward settings. Negative values indicate a greater relative percentage decrease in the provision of evidence-based care in stroke units compared with other ward settings. Other point estimates relevant to the figure are provided in the Supplementary Table 1.
Figure 2.Proportion of patients prescribed secondary prevention medications (A: antihypertensive medication; B: antithrombotic medication; C: lipid lowering medication) at discharge and (D) discharged to the community with a care plan. The vertical line (week 61) indicates the week of the interruption used in this study (1/3/2020, the first coronavirus disease 2019 [COVID-19] related death in Australia). Significant difference in weekly trend between groups prior to interruption (β and 95% confidence intervals [CIs] presented): discharged to the community with a care plan –0.09 (95% CI, –0.17 to –0.01). Significant difference during week of interruption between groups (week 61): discharged to the community with a care plan 3.61 (95% CI, 0.28 to 6.94). Significant difference in weekly trend between groups in post-interruption period: provided antihypertensive medication at discharge 0.58 (95% CI, 0.08 to 1.07); provided antithrombotic medication at discharge 1.08 (95% CI, 0.78 to 1.38); provided lipid lowering medication at discharge 0.69 (95% CI, 0.28 to 1.09). β in a period signifies the the difference in the average weekly percentage change over several weeks (trend) between groups. β during the week of the interruption signifies the difference in a percentage change during that week between groups. Positive values indicate a greater relative percentage increase in the provision of evidence-based care in stroke units compared with other ward settings. Negative values indicate a greater relative percentage decrease in the provision of evidence-based care in stroke units compared with other ward settings. Other point estimates relevant to the figure are provided in the Supplementary Table 2.